AIDSWEEKLY Plus; Monday, May 30, 2005
Staff Medical Writers

"The objective of this paper was to investigate the activation and coreceptor CCR5, CXCR4 expression of T lymphocytes in HIV/AIDS patients of China, and to study their association with disease progression.

"Seventy-seven HIV/AIDS patients and thirteen normal controls were enrolled and three-color flow-cytometry was used to detect the activation marker HLA-DR, CD38 and the coreceptor CCR5, CXCR4 expression on T lymphocytes in whole blood samples taken from the patients and the controls," investigators in China report.

"The HLA-DR, CD38 and CCR5 expression on CD4, CD8+ T cells in AIDS patients was higher than in asymptomatic HIV-1 infected patients and normal controls (p<0.05). The activation and CCR5 expression on T lymphocytes significantly correlated with CD4+ T lymphocyte number and viral load," wrote H. Shang and colleagues at the China Medical University in Shenyang.

"The activation on T lymphocytes and the expression of CCR5 on T lymphocytes in HIV/AIDS patients of China are significantly correlated with disease progression," the authors concluded.

Shang and colleagues published their study in the Journal of Clinical Immunology (Activation and coreceptor expression of T lymphocytes in HIV/AIDS patients of China. J Clin Immunol. 2005 Jan;25(1):68-72.

For additional information, contact H. Shang, China Med University, AIDS Research Center, First Affiliated Hospital, Shenyang 110001, People's Republic of China.

The publisher of the Journal of Clinical Immunology can be contacted at: Springer, Plenum Publishers, 233 Spring St., New York, NY 10013, USA.

Keywords: Shenyang, China, Activation, HIV-1 CCR5, Disease Progression, Risk Factor, T Lymphocyte.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Shang H, Zhang Z, Jiang Y, et al., Activation and coreceptor expression of T lymphocytes in HIV/AIDS patients of China, J Clin Immunol. 2005 Jan;25(1):68-72.

PubMED Related articles Search

050530
AW050514

Copyright © 2005 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.